Opterion Health — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Opterion Health is a clinical-stage biotech targeting the multi-billion-dollar dialysis market with a disruptive solution for peritoneal dialysis. Its lead product, Opterion ODR, is a novel osmotic driver composed of a proprietary polysaccharide (Decadextrin) and maltose, designed to provide effective fluid removal without the glucose-related metabolic complications of current standards. The company aims to make PD a more attractive, longer-lasting, and safer alternative to hemodialysis, potentially capturing significant market share in a large and growing renal disease sector.

NephrologyEnd-Stage Renal Disease

Technology Platform

Proprietary non-glucose-based osmotic driver for peritoneal dialysis, utilizing a novel polysaccharide (Decadextrin) and maltose to enable effective fluid and waste removal while minimizing metabolic stress and peritoneal membrane damage.

Opportunities

The primary opportunity is to catalyze a major shift from hemodialysis to peritoneal dialysis by solving its key limitation—glucose-induced complications.

This could allow Opterion to capture a significant portion of the $80B+ dialysis market.

Additionally, improving outcomes for diabetic ESRD patients (45% of the dialysis population) represents a large, specific, and high-need sub-market.

Risk Factors

The technology is unproven in clinical trials, facing significant regulatory and development risk.

As a pre-revenue startup, the company is dependent on raising substantial capital in a competitive funding environment.

Post-approval, it must compete with entrenched giants like Fresenius and Baxter in a conservative healthcare segment.

Competitive Landscape

The dialysis market is dominated by large players like Fresenius and DaVita in hemodialysis, and Baxter in peritoneal dialysis solutions (e.g., glucose-based fluids and Icodextrin). Opterion's direct competition is Baxter's Icodextrin, which is only approved for long dwells. Opterion aims to compete by offering a superior, full-day osmotic driver that avoids glucose entirely, positioning itself as a disruptive innovator in a niche currently served by a single sub-optimal product.

More companies in Small Molecule Drugs →More companies in Switzerland →